Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 16,149 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Melanoma
Interventions: DNX-2401; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Onychomycosis
Interventions: AN2690, AN2690 Solution, Vehicle, Sodium Lauryl Sulfate, 0.5%; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions: GM-CT-01, 5-fluorouracil; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 4
States / cities: Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more

Conditions: Breast Cancer
Interventions: goserelin, letrozole, leuprolide acetate, conventional surgery; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Monica, California • Santa Rosa, California + 11 more

Conditions: Melanoma, Skin Cancer
Interventions: Cisplatin, Vinblastine, Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions: Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid; Biological · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: PVX-410, Durvalumab, Hiltonol; Biological · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts • New York, New York

Conditions: Breast Cancer
Interventions: alvocidib, docetaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
Interventions: Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Breast Cancer Surgery
Interventions: Positron Emission Mammography (PEM); Device
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Diabetic Foot Ulcer
Interventions: Iodosorb, Solosite gel; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Melanoma, Stage IV Skin Melanoma
Interventions: Recombinant Interferon Alfa, Bevacizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Breast Cancer
Interventions: Physical activity counseling; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Melanoma
Interventions: MK-3475, Peginterferon alfa-2b; Drug
Lead sponsor: Hassane M. Zarour, MD; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dupuytren's Disease
Interventions: Not listed
Lead sponsor: Robert Hotchkiss; Other
Eligibility: 35 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: therapeutic allogeneic lymphocytes; Biological
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Vitiligo
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Alopecia Areata
Interventions: bempikibart (ADX-914); Drug
Lead sponsor: Q32 Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more

Conditions: Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review; Procedure · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions: EFG PH20 SC, PBO; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more

Conditions: Prevention
Interventions: Intervention Group; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Golden, Colorado

Conditions: Breast Cancer
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Breast Cancer, Colorectal Cancer
Interventions: Telephone-Based exercise intervention; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more

Search by objective public record fields.

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

Cumulative Irritation Test

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Physical Activity Promotion in Cancer Follow-Up Care

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Validation of Two New Questionnaires for Dupuytren's Disease

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Daily Topical Rapamycin for Vitiligo

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Using Physical Tracking to Predict Sunburn

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

The Active After Cancer Trial (AACT)